alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
## RE CE IVED O

PPT CB I C 

# ll . SOCMA Society of Chemical l'1anuf<Jct11rers & Affiliates

Document Control Office (7407 M) Office of Pollution Prevention and Toxics (OPPT) Environmental Protection Agency EPA East Building, Room E6428 (202-564-8930) 1201 Constitution Avenue , NW Washington , DC 20460 Attention: TSCA Section 4 Docket 

### 10 Number EPA-HQ-OPPT -2009-0112 To Whom It May Concern: January 28, 2015
CBIC Control Number 

# 363905 ,....., c= en 

### -n rr1 C1? N 

### -o ::I: .I:" 

## . . 0

RE: Testing of Certain High Production Volume Chemica ls; Third Group of Chemicals. Federal Register 76 (204), 65385-65410, October 21, 2011 . 1-Propanesulfonic acid, 2-hydroxy-3-(2-propen- 1-yloxy)-, sodium salt (1:1) (CAS No. 52556-42-0) Extension Request for Final Reporting Deadline The COPS-1 Consortium, a cost-sharing consortium formed and managed under the Society of Chemical Manufacturers and Affiliates (SOCMA) submits this request to extend the final report ing deadline unde r the subject test rule for 1-propanesulfonic acid, 2- hydroxy-3 -(2 - propen-1-yloxy)- , sodium salt (1:1) (CAS No. 52556-42-0), also known as COPS-1
. On June 16, 20 14 the COPS-1 Consortium subm itted a new test plan to respond to a request from EPA' s Dr. Paul Lewis on April 28, 2014 to repeat the gene mutation and chromosome aberration studies
. The results of those tests had been submitted earlier (August 28, 2013) but were found by EPA reviewers to be inadequate to satisfy the HPV 3 test rule. The Consortium agreed to repeat those studies accordingly and submit final reports by the deadline of February 16 , 2015. The stud ies to be repeated are: • Gene Mutations : Bacterial Reverse Mutation Test (in vitro): 40 CFR 799
.9510 (OECD471 )
. • Mammalian (chromosoma l damage) : In vitro mamm a lian chromosome aberration, 40 CFR 799.9537 (OECD473). O:;:;o -orq ""'OC ) -tr.J 

### 0<: C:Or-1 

### ocJ



# r/;ff .Z-jZf 

# _.1 pvU

## tl

.... ChemStewards AllulGtMio SOCMA 1 HSO f"l St NW**~UI!C'** 100 • Was l11ngwn, DC 20036 5810 •Tel: 202. 12.1 4 100 • F.tx: 202. 2.% 8120 .. d ...**~OUilJ..COill**The Consortium requests an extension to July 31 , 2015
. A delay in receipt of EPA' s review of the test plan submitted June 16 , 2014 prevented scheduling the repeat studies sooner. Because of other commitments scheduled, the contract laboratory that will do the work is unable to start until February 2015
. The requested extension allows sufficient t i me for the lab to complete the studies and prepare final reports and for the consortium members to review the reports and submit them to EPA. Members of the COPS-1 consortium are the following companies: AkzoNobel Surface Chemistry LLC Ashland Inc. Bimax Inc. GE Water & Process Technologies So lvay USA , Inc
. Thank you for considering th is request. For further information or questions , please contact the undersigned directly at 202-721-4154 or helmest@socma
.com .

Cc : Dr
. John Schaeffer C. Tucker Helmes , Ph
. D
. Executive Director COPS-1 Consortium
# United States Court **of Appeals**  **f or the Fifth Circuit** 

**____________** No. 22

- 60387 Summary Calendar

**____________ Abraham Nee Ntreh**  **; Marcia Maureen Witter,**

Petitioners **,**

versus **Merrick Garland,** U.S. Attorney General **,** Respondent

**.**

**______________________________** Petition for Review of an Order of the Board of Immigration Appeals Agency Nos. A042 395 049, A042 395 050

**___________ ___________________**  Before **Smith, Southwick,** and **Douglas,** Circuit Judges

**. Per Curiam**  **:** ***** Abraham Nee Ntreh, a native and citizen of Ghana, and Marcia Maureen Witter, a native of Jamaica and citizen of the United Kingdom, petition for review of an order of the Board of Immigration Appeals (BIA) denying their motion for reconsideration of the deni al of their third motion to reopen , both of which arose under 8 C.F.R. § 1003.2

. We lack jurisdict ion

**_____________________**

* This opinion is not designated for publication. See **5th Cir**

**. R** 

**.** 47.5. United States Court of Appeals Fifth Circuit 

### FILED May 15, 2023 Lyle W. Cayce Clerk Case: 22-60387 Document: 00516750127 Page: 1 Date Filed: 05/15/2023No. 22

- 60387

2 to consider the BIA’s discretionary denial of the petitioners’ regulatory motion to reconsider. See Gonzales

- Cantu v. Sessions , 866 F.3d 302, 306 & n.5 ( 5th Cir. 2017 ) ; § 1003.2(a). The petition for review is **DISMISSED** for want of jurisdiction, and t he motion for summary affirmance is **DENIED**

. Case: 22-60387 Document: 00516750127 Page: 2 Date Filed: 05/15/2023
[Federal Register Volume 89, Number 178 (Friday, September 13, 2024)]
[Notices]
[Page 74940]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-20825]



[[Page 74940]]

=======================================================================
-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[FRL OP-OFA-143]


Environmental Impact Statements; Notice of Availability

    Responsible Agency: Office of Federal Activities, General 
Information 202-564-5632 or https://www.epa.gov/nepa.

Weekly receipt of Environmental Impact Statements (EIS)
Filed August 30, 2024 10 a.m. EST Through September 9, 2024 10 a.m. EST
Pursuant to 40 CFR 1506.9.

Notice

    Section 309(a) of the Clean Air Act requires that EPA make public 
its comments on EISs issued by other Federal agencies. EPA's comment 
letters on EISs are available at: https://cdxapps.epa.gov/cdx-enepa-II/public/action/eis/search.

EIS No. 20240162, Draft, BLM, NV, Greenlink North Transmission Project, 
Comment Period Ends: 12/11/2024, Contact: Brian L. Buttazoni 775-861-
6491.

    Dated: September 9, 2024.
Timothy Witman,
Acting Director, NEPA Compliance Division, Office of Federal 
Activities.
[FR Doc. 2024-20825 Filed 9-12-24; 8:45 am]
BILLING CODE 6560-50-P
BIE

https://secure.cds2.com:8080/main.html?download&weblink=ba7fb55f3f312c4157404ab0e2456183&r ealfilename=BIE - v3.0.pdf
**Exhibit 31.3**
**Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002**
I, Steven A. Newman, certify that:
 1. I have reviewed this quarterly report of Xybernaut Corporation;  2. Based on my knowledge, this quarterly report does not contain anyuntrue statement of a material fact or omit to state a material factnecessary to make the statements made, in light of the circumstancesunder which such statements were made, not misleading with respect tothe period covered by this quarterly report;  3. Based on my knowledge, the financial statements, and other financialinformation included in this quarterly report, fairly present in allmaterial respects the financial condition, results of operations andcash flows of the registrant as of, and for, the periods presented inthis quarterly report;  4. The registrant’s other certifying officers and I are responsible forestablishing and maintaining disclosure controls and procedures (asdefined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for theregistrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosurecontrols and procedures to be designed under our supervision, to ensure thatmaterial information relating to the registrant, including its consolidatedsubsidiaries, is made known to us by others within those entities, particularlyduring the period in which this quarterly report is being prepared;
(b) Evaluated the effectiveness of the registrant’s disclosure controls andprocedures and presented in this report our conclusions about the effectivenessof the disclosure controls and procedures, as of the end of the period coveredby this report based on such evaluation; and
(c) Disclosed in this report any change in the registrant’s internal controlover financial reporting that occurred during the registrant’s most recentfiscal quarter that has materially affected, or is reasonably likely tomaterially affect, the registrant’s internal control over financial reporting;and
 5. The registrant’s other certifying officers and I have disclosed, basedon our most recent evaluation of internal control over financialreporting, to the registrant’s auditors and the audit committee of theregistrant’s board of directors (or persons performing the equivalentfunctions):
(a) All significant deficiencies and material weaknesses in the design oroperation of internal control over financial reporting which are reasonablylikely to adversely affect the registrant’s ability to record, process,summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or otheremployees who have a significant role in the registrant’s internal control overfinancial reporting.
August 6, 2004
XYBERNAUT CORPORATION     /s/ STEVEN A. NEWMAN   Steven A. Newman President, Chief Operating Officer and Vice Chairman of the Board of Directors
EX-10.5









EXHIBIT 10.5




November 10, 2008




Advanced Viral Research Corp.

6 Executive Plaza, Suite 283

Yonkers, New York 10701





     Re: Employment



To Whom It May Concern:




This is to set forth our agreement regarding the payment of my salary.




From the two week pay period ending October 17, 2008 until the Triggering Event (as defined
below), the Company shall pay 40% of my base salary and all other cash amounts obligated to be
paid by the Company to me under our employment arrangement (e.g. $101,800 per annum) shall be
deferred until the Company (i) acquires net proceeds of at least $3.0 million from the sale of
the Company’s assets or securities; or (ii) consummates a merger transaction with the surviving
entity having at least $3.0 million in cash availability (the “Triggering Event”).




Upon the occurrence of the Triggering Event, all amounts deferred hereunder shall be paid to me
in one lump sum.



Except as otherwise specifically provided in this letter agreement, the terms of our arrangement
shall remain in full force and effect



This letter agreement may be executed in any number of counterparts, all of which taken together
shall constitute one letter agreement.



	 	 	 	 	 
	 	Sincerely,

 	 
	 	/s/ Martin Bookman
 	 
	 	Martin Bookman 	 
	 	 	 
	 



Agreed and Acknowledged as of October 17, 2008




ADVANCED VIRAL RESEARCH CORP.




By: /s/ Stephen Elliston, Chief Executive Officer and President
Exhibit 10.6.5

LOGO

MEMORANDUM



|    |  |        |  |       |  |                 |  | 
|--- |  | ------ |  | ----- |  | --------------- |  | 
|To: |  | [Name] |  | Date: |  | [date of award] |  | 

We are extremely pleased to inform you that the Compensation Committee of the Board of Directors of Energy
Transfer Partners, L.P. (Energy Transfer) has granted you an Award representing [                    ] common units under the
Energy Transfer Partners, L.P. Amended and Restated 2004 Unit Award Plan (the Unit Award Plan). This Award is subject to vesting over five (5) years, with 20% of this Award to be vested upon each anniversary of this Award
subject to your continued employment with Energy Transfer as of each such anniversary date. Any portion of this Award that does not vest will be forfeited. Common units will be issued to you upon vesting of the Award as described below. You will be
entitled to receive regular quarterly cash distributions on units issued to you upon vesting, with such distributions to be made at the same times and in the same amounts as other outstanding common units. This Award is subject to the terms and
conditions of the Unit Award Plan.

Please note that like any compensation arrangement, Awards under the Unit Award Plan are to be kept confidential unless
required by SEC disclosure regulations.

Thanks for your continuing contributions to our efforts. It is a pleasure for us to be associated with you in
building an even greater company. Enclosed are two originals for your execution. Please retain one for your file and forward the other to Energy Transfer Partners, 3738 Oak Lawn Avenue, Dallas, Texas 75219, Attention: Thomas P. Mason.

Accepted:



|       |  |  |  |  |  |  |  |                                                   |  |                                                     
|------ |  |  |  |  |  |  |  | ------------------------------------------------- |  | ----------------------------------------------------
|       |  |  |  |  |  | 
|[Name] |  |  |  |  |  |  |  | Kelcy Warren CHAIRMAN
AND CHIEF EXECUTIVE OFFICER
|       |  |  |  |  |  |  |  | BY:                                               |  | ENERGY TRANSFER PARTNERS G.P., L.P., GENERAL PARTNER
|       |  |  |  |  |  |  |  | BY:                                               |  | ENERGY TRANSFER PARTNERS, L.L.C., GENERAL PARTNER   
|       |  |  |  |  | 
|Date:  |  |  |  |  |  |  |  | Date:                                             |  |                                                     
|       |  |  |  | 
|       |  |  |  |  |  |  |  |                                                  
|       |  |  |  |  |  |  |  | Brian J. Jennings CHIEF
FINANCIAL OFFICER        
|       |  |  |  |  |  |  |  | BY:                                               |  | ENERGY TRANSFER PARTNERS G.P., L.P., GENERAL PARTNER
|       |  |  |  |  |  |  |  | BY:                                               |  | ENERGY TRANSFER PARTNERS, L.L.C., GENERAL PARTNER   
|       |  |  |  |  | 
|       |  |  |  |  |  |  |  | Date:                                             |  |
<PAGE>   1
                                                                      Exhibit 23


                          INDEPENDENT AUDITORS' CONSENT

We consent to the incorporation by reference in the Registration Statements of
Value City Department Stores, Inc. on Form S-8 (File Nos. 33-44207, 33-50198,
33-55348, 33-55350, 33-78586, 33-80588, 33-92966, 333-15957, 333-15961, and
333-66239) and on Form S-3 (File No. 333-66247) of our report dated October 2,
1998, appearing in the Annual Report on Form 10-K of Value City Department
Stores, Inc. for the year ended August 1, 1998.



                                                          Deloitte & Touche  LLP

Columbus, Ohio
October 28, 1998
exv10w14






Exhibit 10.14




DEUTSCHE BANK TRUST COMPANY AMERICAS

60 WALL STREET

NEW YORK, NEW YORK 10005




October 7, 2008




Wellman, Inc.

1041 521 Corporate Center Drive

Fort Mill, South Carolina 29715

Attention: Chief Financial Officer

and Treasurer and Chief Accounting Officer




Re: Wellman, Inc. Credit Agreement dated as of February 27, 2008




     Reference is hereby made to that certain Credit Agreement, dated as of February 27, 2008, by
and among Wellman, Inc. (the “Funds Administrator”) and the other Borrowers party thereto,
as debtors and debtors in possession, as Borrowers, the Lenders from time to time party thereto,
Deutsche Bank Trust Company Americas, as Administrative Agent (in such capacity, the
“Administrative Agent”) and Collateral Agent, and the other agents signatory thereto (as
amended, restated, supplemented, or otherwise modified from time to time, the “Credit
Agreement”). Capitalized terms used herein and not otherwise defined herein shall have the
meanings assigned to such terms in the Credit Agreement.



     The undersigned Administrative Agent, on behalf of the Majority Lenders, hereby consents to
the Funds Administrator’s request that Section 9.1(i)(xv) of the Credit Agreement be amended by
deleting the date “October 7, 2008” in sub clause (iii) thereof and replacing it with “October 20,
2008”.



     Except as expressly provided herein with respect to Section 9.1(i)(xv) of the Credit
Agreement, (i) this letter shall not be construed as a consent, waiver or other modification with
respect to any term, condition, or any other provision of the Credit Agreement or any other Loan
Document, and each of the Loan Documents shall remain in full force and effect, and (ii) neither
this letter, nor any other communication between the Administrative Agent and the Funds
Administrator or any other Borrower shall be deemed to be a waiver, modification, or release of any
Default or Event of Default, whether such Default or Event of Default arose or arises before, on or
after the date hereof and whether or not known to the Administrative Agent.



[remainder of page intentionally blank]




 









 





	 	 	 	 	 
	 	Very truly yours,



DEUTSCHE BANK TRUST COMPANY

AMERICAS, as Administrative Agent

 	 
	 	By:  	/s/ David J. Bell
 	 
	 	 	Title: Managing Director 	 
	 	 	 
	 	By:  	                                         /s/ Dusan Lazarov
 	 
	 	 	Title: Vice President 	 
	 	 	 	 
	 


Acknowledged and agreed as of

this 7 day of October, 2008




WELLMAN, INC.




	 	 	 	 	 
	By:  	/s/ Keith R. Phillips
 	 
	 	Title: Chief Financial Officer
II 

115TH CONGRESS 

1ST SESSION S. 241 

To prohibit Federal funding of Planned Parenthood Federation of America. 

IN THE SENATE OF THE UNITED STATES 

JANUARY 30, 2017 

Mrs. ERNST (for herself, Mr. CORNYN, Mr. CRUZ, Mr. BLUNT, Mr. ROBERTS, 

Mr. SCOTT, Mr. PAUL, Mr. LANKFORD, Mr. MORAN, Mr. RUBIO, Mr. 

DAINES, Mr. HOEVEN, Mr. SULLIVAN, Mr. SASSE, Mrs. FISCHER, Mr. 

CRAPO, Mr. KENNEDY, Mr. LEE, Mr. RISCH, Mr. WICKER, Mr. INHOFE, 

Mr. CORKER, Mr. GRASSLEY, and Mr. GRAHAM) introduced the following 

bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions 

A BILL 

To prohibit Federal funding of Planned Parenthood 

Federation of America. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Protect Funding for 

5 Women’s Health Care Act’’. 

6 SEC. 2. FINDINGS. 

7 Congress finds as follows: 


rfrederick on DSKBCBPHB2PROD with BILLS
2 

•S 241 IS

1 (1) State and county health departments, com2 munity health centers, hospitals, physicians offices, 

3 and other entities currently provide, and will con4 tinue to provide, health services to women. Such 

5 health services include relevant diagnostic laboratory 

6 and radiology services, well-child care, prenatal and 

7 postpartum care, immunization, family planning 

8 services including contraception, sexually trans9 mitted disease testing, cervical and breast cancer 

10 screenings, and referrals. 

11 (2) Many such entities provide services to all 

12 persons, regardless of the person’s ability to pay, 

13 and provide services in medically underserved areas 

14 and to medically underserved populations. 

15 (3) All funds no longer available to Planned 

16 Parenthood will continue to be made available to 

17 other eligible entities to provide women’s health care 

18 services. 

19 SEC. 3. PROHIBITION. 

20 (a) IN GENERAL.—Notwithstanding any other provi21 sion of law, no Federal funds may be made available to 

22 Planned Parenthood Federation of America, or to any of 

23 its affiliates, subsidiaries, successors, or clinics. 

24 (b) RULES OF CONSTRUCTION.—Nothing in this Act 

25 shall be construed to— 


rfrederick on DSKBCBPHB2PROD with BILLS
3 

•S 241 IS

1 (1) affect any limitation contained in an appro2 priations Act relating to abortion; or 

3 (2) reduce overall Federal funding available in 

4 support of women’s health. 

Æ 


rfrederick on DSKBCBPHB2PROD with BILLS
EXHIBIT 32.1

     Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
                                  CERTIFICATION

I, Mark T. Walton certify that:

1. I have reviewed this quarterly  report on Form 10-Q of Travis Boats & Motors,
Inc.;

2. Based on my  knowledge,  this  quarterly  report  does not contain any untrue
statement of a material fact or omit to state a material fact  necessary to make
the statements made, in light of the  circumstances  under which such statements
were made, not  misleading  with respect to the period covered by this quarterly
report;

3.  Based  on my  knowledge,  the  financial  statements,  and  other  financial
information  included in this quarterly  report,  fairly present in all material
respects the financial condition,  results of operations,  and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4.  The  registrant's  other  certifying  officer  and  I  are  responsible  for
establishing and maintaining  disclosure  controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the  registrant  and have: a) Designed
such  disclosure  controls and  procedures to ensure that  material  information
relating to the registrant,  including its  consolidated  subsidiaries,  is made
known to us by others within those entities,  particularly  during the period in
which this quarterly report is being prepared; b) Evaluated the effectiveness of
the registrant's  disclosure controls and procedures as of a date within 90 days
prior to the filing date of this quarterly report (the "Evaluation  Date");  and
c) Presented in this quarterly report our conclusions about the effectiveness of
the  disclosure  controls  and  procedures  based  on our  evaluation  as of the
Evaluation Date;

5. The registrant's other certifying officer and I have disclosed,  based on our
most recent evaluation,  to the registrant's auditors and the audit committee of
the  registrant's  board of  directors  (or persons  performing  the  equivalent
functions):  a) All  significant  deficiencies  in the  design or  operation  of
internal  controls  which could  adversely  affect the  registrant's  ability to
record,  process,  summarize,  and report financial data and have identified for
the registrant's  auditors any material weaknesses in internal controls;  and b)
Any fraud, whether or not material,  that involves management or other employees
who have a significant role in the registrant's internal controls; and

6. The  registrant's  other  certifying  officer  and I have  indicated  in this
quarterly report whether there were significant  changes in internal controls or
in other factors that could significantly affect internal controls subsequent to
the date of our most recent  evaluation,  including any corrective  actions with
regard to significant deficiencies and material weaknesses.

                                                /s/ Mark T. Walton
                                     -------------------------------------------
                                     Mark T. Walton, President

Date: February 17, 2004
**EXHIBIT 32.1**

**CERTIFICATION PURSUANT TO 18U.S.C. SECTION 1350,**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THESARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Qof CollaGenex Pharmaceuticals, Inc. (the “Company”) for the period ended June30, 2007 as filed with the Securities and Exchange Commission on the datehereof (the “Report”), the undersigned, Colin W. Stewart, Chief ExecutiveOfficer of the Company, and Nancy C. Broadbent, Chief Financial Officer of theCompany, each hereby certifies, pursuant to 18 U.S.C. Section 1350, that:

### (1)           The Report fully complies withthe requirements of Section 13(a) or 15(d) of the Securities Exchange Act of1934; and

### (2)           The information contained inthe Report fairly presents, in all material respects, the financial conditionand results of operations of the Company.

|                             | /s/ Colin W.  Stewart    |
|-----------------------------|--------------------------|
| Dated:  August 9, 2007 | Colin W. Stewart         |
|                        | Chief Executive  Officer |
|                        |                     |
|                        |                     |
|                        | /s/ Nancy C.  Broadbent  |
| Dated:  August 9, 2007 | Nancy C. Broadbent       |
|                        | Chief Financial  Officer |

 

----